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The Lung Science Conference 2020 brought together leading experts in the field to discuss the 
latest cutting-edge science, as well as various career development opportunities for early career 
members https://bit.ly/2XZ5YGQ
 Every year, the European Respiratory Society (ERS) 
organises the Lung Science Conference (LSC) in 
Estoril, Portugal, to discuss basic and translational 
science. The topic of the LSC 2020 was “Metabolic 
alterations in lung ageing and disease”. In addition 
to an outstanding scientific programme, the 
LSC provides excellent opportunities for career 
development and inclusion of Early Career Members 
(ECMs). All scientific and poster sessions are chaired 
by an ECM who is paired with a senior faculty 
member to allow ECMs to become acquainted with 
session chairing. In addition, 40 travel bursaries are 
made available to abstract authors and all bursary 
recipients are invited to take part in a mentorship 
lunch. Moreover, there is a session organised by 
the Early Career Members Committee (ECMC) 
dedicated to career development. Here, we describe 
the scientific highlights of LSC 2020 for those who 
could not attend.
The ERS presents several awards at the LSC 
and here we will highlight all winners of the LSC 
2020 awards. The five highest ranked abstracts 
from ECMs are presented during the Young 
investigator session. Patricia Ogger (UK) was 
presented with the William MacNee Award for the 
best presentation in this session. Several abstracts 
were selected for programmed oral presentations 
and Renata Jurkowska (UK) was presented with the 
inaugural Geoffrey Laurent Award for the best oral 
presentation. Moreover, the organisers presented 
eight Distinguished Poster awards to Anne-Sophie 
Lamort (Germany), Julia Frankenberg Garcia (UK), 
Johnatas Silva (UK), Pauline Esteves (France), 
Claudio Bussi (UK), Elodie Picard (France), Felix 
Ritzmann (Germany) and Alen Faiz (Australia) for 
their excellent contributions during the poster 
session.
Opening lecture
The introduction and opening lecture was given by 
Luke O’Neill (Dublin, Ireland). He introduced the 
term “immunometabolism” [1] and discussed its 
potential importance in drug efficacy. Prof. O’Neill 
mentioned that many drugs, although very promising 
in pre-clinical stages, were not proven to be efficient 
in clinical trials. This may be because although the 
immunology and pathology was studied and targeted, 
the influence of the metabolism was understudied. To 
move the field forward, these effects and metabolic 
mechanisms need to be further studied in order to 
“boost efficacy” of drugs, and ultimately be able to 
more effectively treat lung diseases such as asthma 
and chronic obstructive pulmonary disease (COPD). 
He further discussed the role of cell death, particularly 
how caspases and inflammasomes can affect 
homeostasis, being potential targets for improvement 
of drugs and patient response.
The nucleotide-binding domain leucine-rich-
containing family pyrin domain-containing-3 
(NLRP3) inflammasome is a sensor for metabolic 
disturbance and that is why the NLRP3 inhibitor 
MCC950 (also called diarylsulfonylurea cytokine 
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release inhibitory drug (CRID3)) was considered as 
a “game changer” [2]. Recent studies have specified 
the mechanisms of CRID3, indicating that inhibitory 
effects are exerted via the NAIP, CIITA, HET-E and 
TP1 domain with NTPase activity (NACHT) of NLRP3 
[3], and reduce inflammation in murine airway and 
skin inflammatory disease models [4, 5].
Caspases play a role in inflammatory diseases 
and caspase-11 has been shown to promote allergic 
airway inflammation [6]. When performing studies 
in caspase-11 knockout mice, there is reduced 
tissue inflammation by histology, decreased total 
cell counts from bronchoalveolar lavage fluid and, 
importantly, eosinophil reduction in the knockout 
animals. Caspase-11 corresponds to caspase-4/5 in 
humans. Analysis of sputum samples from asthma 
patients revealed increased caspase-4 levels, as well 
as elevated levels of NLRP3, caspase-1, caspase-5 
and interleukin (IL)-1β [7].
The Warburg effect was first described by Otto 
Warburg in the context of cancer, observing that 
cancer cells use glycolysis as their main metabolic 
pathway, even in the absence of hypoxia. In his 
talk, Prof. O’Neill highlighted the importance of 
metabolism for cell function and as a driver of 
disease, and showed studies linking glucose levels 
in the lungs to areas of fibrotic foci in patients with 
idiopathic pulmonary fibrosis (IPF) [8]. Fibrosis is 
considered to result from dysregulated wound 
healing and no cure is currently available. New 
drugs, such as pirfenidone and nintedanib, slow 
disease progression but a better understanding of 
the disease is urgently needed. Investigating cell 
metabolism in the context of pulmonary fibrosis 
could offer new therapeutic opportunities, as clinical 
studies [9–11] and pre-clinical fibrosis models [12] 
indicate a dependence of fibrotic foci on glucose 
and glycolysis.
Pyruvate kinase M2 has been shown to activate 
Warburg metabolism in M2 macrophages and is 
therefore a critical determinant in inflammatory 
responses [13]. In this opening lecture, Prof. 
O’Neill emphasised the importance of the Krebs 
cycle and the products it generates, one of them 
being itaconate. Besides antibacterial functions, 
itaconate has recently been shown to limit NLPR3-
dependent cytokine release, such as that of IL-1β 
from peripheral blood mononuclear cells in patients 
with cryopyrin-associated autoinflammatory 
syndromes. When lipopolysaccharide and itaconate 
were administered at the same time, an improved 
survival rate was observed [14, 15].
The main and important message from Prof. 
O’Neill was that “metabolism is the driver (of 
disease) while genes are the passengers". With 
this statement, he pointed towards the fact that 
diseases increasing over the past decades have 
not emerged due to genetic variation, while 
environmental exposure stimuli, diet and behaviour 
have drastically changed – and so has metabolism. 
Metabolism is poised to sense these modifications 
and thus, in turn, drives changes in gene expression 
that are causing disease or imbalance of health 
status. Therefore, understanding the underlying 
metabolic changes may improve therapeutic targets 
in the future [16].
Immunometabolism 
and inflammageing
Craig Wheelock (Stockholm, Sweden) kicked of the 
first session by discussing the metabolic profiling 
of severe asthma, and its implications for disease 
phenotyping and treatment. Metabolomic analysis 
provides an integrative molecular signature of the 
genome, transcriptome and proteome, which 
ultimately can be linked to a disease phenotype. 
Urinary eicosanoids have been demonstrated 
to identify molecular phenotypes of asthma and 
eicosanoids may be important components that aid 
in our understanding of the biochemical processes 
that drive asthma severity.
Thereafter, Annika Karger (Bad Nauheim, 
Germany) discussed how the long coding RNA 
ADPGK-AS1 can control antitumour immunity 
in macrophages via metabolic reprogramming. 
She concluded that enhanced understanding and 
potential targeting of this long coding RNA could 
have the potential to serve as a future therapeutic 
approach in lung cancer treatment.
Next, Rajkumar Savai (Bad Nauheim, Germany) 
reviewed the impact of metabolic reprogramming 
of tumour-associated macrophages on lung cancer 
progression. He discussed the use of a variety of 
novel high-resolution small animal in vivo imaging 
techniques to gain insight into tumour evolution 
and progression. Furthermore, he provided an 
exciting set of data describing the potential to 
reprogram tumour-associated macrophages 
towards antitumour responses [17].
The last presenter of the first session, Carol 
Liang (Los Angeles, CA, USA), showed a reduction 
in the number and repair capacity of type II alveolar 
epithelial cells (AECII) in the lung of both ageing 
and IPF experimental mouse models using single-
cell sequencing. Furthermore, she showed that 
zinc transporter 8 levels are attenuated in the 
AECII of these models, suggesting deficient zinc 
metabolism as a shared mechanism in ageing and 
IPF. Exogenous zinc treatment was able to replenish 
AECII differentiation in the lungs of IPF patients but 
not in ageing mice.
Mitochondrial dysfunction 
in lung ageing and disease
Recent literature suggests a key role for 
mitochondrial dysfunction in lung ageing, and 
pathogenesis of lung diseases such as COPD and 
asthma [18, 19]. Emerging evidence shows that 
mitochondria are implicated in the regulation of 
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critical cellular processes of cells of the airways 
such as inflammation, oxidative stress and cell 
death pathways, alongside their traditional role as 
the powerhouse of the cell [19, 20]. That is why the 
focus of this second session was on mitochondrial 
dysfunction in lung ageing and disease.
Matt Whiteman (Exeter, UK) opened this session 
by describing that mitochondrion-targeted hydrogen 
sulfide (H2S) suppresses and reverses cigarette 
smoke-induced inflammasome activity and lung 
injury in experimental COPD, and showed results 
of an in vivo animal smoke exposure study. This 
research built further on previous findings suggesting 
a central role for H2S in the development of COPD 
and one of the key processes involved in COPD 
pathogenesis, i.e. inflammation, which appointed 
H2S as a potential therapeutic target [21, 22].
The next talk focussed on the development of 
asthma, in which the role of mitochondrial (dys)
function is increasingly gaining attention. As airway 
remodelling, i.e. airway smooth muscle hypertrophy 
and hyperplasia, is a crucial hallmark involved in 
the pathogenesis of asthma [23], Thomas Trian 
(Bordeaux, France) discussed mitochondria 
located in airway smooth muscle as a driver of 
airway hyperresponsiveness in asthma. Elevated 
mitochondrial mass, increased abundance of key 
regulators of mitochondrial biogenesis, elevated 
carnitine palmitoyltransferase 2 protein levels 
and upregulation of oxidative phosphorylation 
were shown in in vitro studies investigating airway 
smooth muscle cells of asthma patients.
Thereafter, an ECM, Thomas Meul (Munich, 
Germany), demonstrated that mitochondrial 
metabolism is a regulator of cellular proteostasis 
in a short oral presentation. In mitochondrial 
DNA-mutated mice, accumulation of NADH, 
and decreased levels of protein synthesis and 
degradation were observed. Resupplying those 
mice with aspartate, an important regulator of the 
malate–aspartate shuttle involved in translocation 
of electrons over the mitochondrial inner 
membrane, reactivated the metabolic system (i.e. 
shift from oxidative phosphorylation to glycolysis) 
and rescued proteostasis.
In the second part of the session, Suzanne 
Cloonan (Dublin, Ireland) discussed the role of 
mitochondrial iron in the susceptibility to, and 
pathogenesis and progression of COPD. Besides 
impairment of the immunometabolism of alveolar 
macrophages of smokers and COPD patients 
[24], and the involvement of ferroptosis in COPD 
development, she discussed the central role of 
iron-associated mitochondrial dysfunction in the 
pathogeneses of COPD. This was illustrated by a 
study in which her group showed that preventing 
cigarette smoke-induced mitochondrial dysfunction 
in the structural cells of the airways of mice (e.g. 
iron regulatory protein 2-deficient mice, mice 
treated with a mitochondrial iron chelator or 
mice fed a low-iron diet) protected against the 
development of emphysema and bronchitis [25]. 
This presentation further highlighted the causal role 
that mitochondria, particularly mitochondrial iron, 
play in the development of COPD.
Next, Christy Tulen (Maastricht, the Netherlands) 
focussed on the effect of cigarette smoke exposure 
on the molecular regulation of mitochondrial 
metabolism in human bronchial and AECs. She 
showed that key regulators of mitochondrial 
metabolism, mitochondrial biogenesis and 
mitophagy were disrupted at the gene and protein 
levels in various human smoke exposure models, i.e. 
(un)differentiated primary bronchial epithelial cells 
exposed to cigarette smoke extract (submerged) or 
cigarette smoke (air–liquid interface), and peripheral 
lung tissue of (non-)COPD patients.
Cellular senescence, an indicator of lung ageing, 
is also seen as a driving mechanism involved in 
the pathogenesis of chronic lung diseases and 
considered as a potential therapeutic target [26]. 
Accordingly, Peter Barnes (London, UK) provided 
an overview of his work on senotherapies to target 
cellular senescence in chronic lung diseases 
by discussing potential therapy strategies and 
drugs targeting the phosphoinositide 3-kinase/
mechanistic target of rapamycin (mTOR) signalling 
pathway (e.g. metformin and rapamycin), the 
senescence-associated secretory phenotype (SASP) 
response, activation of sirtuins (i.e. sirtuin 1 and 
6), microRNAs, oxidative stress (e.g. antioxidants), 
mitochondrial function and senolytics [27].
The final presentation of the session was 
provided by Elena Lopez Rodriguez (Berlin, Germany) 
on air space distension preceding spontaneous 
fibrotic remodelling and impaired cholesterol 
metabolism in the absence of surfactant protein C.
Cellular senescence
Reinhold Medina (Belfast, UK) opened this session 
with an excellent overview of the role of endothelial 
cell senescence in the development of chronic 
diseases. He demonstrated that senescent cells 
cannot be defined by a single marker but rather, 
exhibit multiple hallmarks including growth arrest, 
senescence-associated β-galactosidase, DNA 
damage, mitochondrial dysfunction and SASP. 
Interestingly, a diabetic microenvironment triggers 
premature senescence in endothelial cells, which is 
associated with their decreased functionality driven 
by diminished mitochondrial respiration and altered 
mitochondrial ultrastructure. Hence, senolytic drugs 
specifically targeting senescent cells could be an 
attractive therapeutic approach for diabetes and 
other chronic diseases. However, their mechanism 
requires further study, because of potential toxicity 
and off-target effects. Furthermore, senolytics 
will likely need to be used in combination with 
regenerative medicine approaches to trigger the 
repair of the functional blood vessels.
In the second presentation, Joaquim Gea 
(Barcelona, Spain) summarised the newest research 
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on the senescence of muscles during ageing and 
in COPD. Respiratory senescence is caused by an 
interplay of different factors, including genetic 
background, early-life exposures, diet, drugs, 
physical activity and comorbidities, which influence 
muscle structure and function [28, 29]. Muscle 
strength and mass physiologically decline with age 
at a rate that is dependent on physical activity and 
overall health [30]. In COPD, general loss of muscle 
mass is frequent, including limb, intercostal and 
diaphragm muscle mass. Both respiratory and limb 
muscles of COPD patients show oxidative stress, 
signs of damage and metabolic changes. Pulmonary 
hyperinflation and increased airway resistance, 
which are hallmarks of COPD, lead to additional 
strain and functional impairment of respiratory 
muscles. In turn, limb muscle dysfunction in 
COPD, which is characterized by a decrease in 
muscle strength and endurance, accompanied by 
lower metabolic efficiency and increased cellular 
senescence, directly impact the exercise capacity 
of the patients [31].
In the third talk, Christina Brandenberger 
(Hannover, Germany) presented her exciting 
results on the contribution of ageing to impaired 
alveolar repair upon injury. She investigated the 
functional changes in AECII, the main epithelial 
stem cell population of the alveoli, in an acute 
lung injury (ALI) model in young (3 months) and 
old (18 months) mice. Interestingly, she found 
increased senescence and DNA damage markers, 
accompanied by lower proliferation potential, 
exclusively in old AECII cells after induction of injury. 
Similarly, lower expression of surfactant genes 
and impaired surfactant function were specifically 
observed in old AECII compared to young AECII after 
injury. These important findings provide a molecular 
explanation for the worsened pathology and limited 
survival in the elderly patients suffering from ALI, 
and further emphasise the urgency of studying lung 
repair processes in old mice for better translation of 
lung mouse models to human pathologies.
Next, Renata Jurkowska (Cardiff, UK) presented 
a novel and versatile workflow based on tissue 
cryopreservation, which allows long-term storage 
of lung tissue for subsequent profiling using 
next-generation sequencing (NGS) [32]. She 
demonstrated that cryopreservation does not 
compromise cell viability and thereby enables 
isolation of multiple functional cell types (e.g. 
fibroblasts, bronchial epithelial basal cells and AECs) 
from healthy and diseased human lung. Importantly, 
using RNA sequencing (RNA-seq) and Illumina 
EPIC Array (methylation profiling), she found that 
genome-wide gene expression and DNA methylation 
signatures of isolated fibroblasts are maintained 
upon cryopreservation. Finally, high viability of 
cryopreserved lung tissue also enabled generation 
of excellent quality single-cell RNA-seq data from 
human epithelial cells, emphasising the suitability of 
the developed workflow for ’omics profiling of lung 
cells. Development of simple tissue preservation 
methods compatible with biobank infrastructure 
will empower prospective collections of viable 
human lung samples that could be used for cell-type 
resolved NGS-based profiling and disease modelling, 
boosting future basic and translational research.
The session was closed by Herbert Schiller 
(Munich, Germany), who presented data from three 
recent projects. Using state-of-the-art single-cell 
transcriptomic and proteomic profiling of young and 
old mice, he provided exciting insights into cellular 
networks during ageing [33]. He showed that ageing 
leads to increased transcriptional noise, altered 
frequency of epithelial cells in the airways and 
extracellular matrix remodelling. Another project, 
examining the kinetics of mouse lung regeneration, 
led to the discovery of an alveolar progenitor cell 
state specifically induced during injury [34]. These 
progenitor cells, characterised by the expression of 
keratin 8 (Krt8), arise from AECII cells or bronchial 
epithelial club cells, and differentiate into AECI 
cells during repair. Finally, Dr Schiller presented an 
ongoing project aiming to characterise mesenchymal 
populations of the mouse and human lung, and 
to investigate their role during lung repair in the 
bleomycin mouse model. Single-cell profiling of 
enriched mesenchymal cells identified several 
distinct cell types, including mesothelial cells, 
smooth muscle cells and distinctive fibroblast-like 
populations. Interestingly, the fibroblast subtypes 
all had distinct locations in the lung, indicative 
of specialised functions. The cellular origin of the 
injury-induced myofibroblasts in the human lung is 
currently unknown; therefore, these data will provide 
invaluable insights into the role of distinct fibroblasts 
subsets during alveolar injury and repair.
The ageing lung under stress
This session contained two presentations exploring 
different aspects of proteostasis during ageing and 
age-related chronic lung disease. Topics discussed 
included proteasome and immunoproteasome 
activity, the effects of reactive oxygen species (ROS) 
and other metabolites on protein degradation as 
well as protein oxidation and endoplasmic reticulum 
(ER) stress. Silke Meiners (Munich, Germany) started 
this session by linking proteostasis to immune 
activation in the ageing lung. Protein degradation 
in the proteasome is an integral part of proteostasis 
and essential for cell function. Proteostasis is tightly 
linked to immune cell function, as proteasomes 
in immune cells (immunoproteasomes) degrade 
proteins for display via the major histocompatibility 
complex (MHC). In the lung, the immunoproteasome 
is expressed particularly in alveolar macrophages 
and enables the lung to mount adaptive immune 
responses upon intracellular infections [35]. During 
ageing, the activity of the immunoproteasome is 
increased, which might account for increased 
autoimmunity during ageing, although this link 
needs to be further investigated. Furthermore, 
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the immunoproteasome is increased in immune 
cells during ageing-associated IPF and in the 
bleomycin mouse model of pulmonary fibrosis [36]. 
Recently, Prof. Meiners has shown that ROS can 
affect proteostasis, while the proteasome complex 
becomes unstable in lung epithelial cells and mouse 
lungs after smoke exposure, indicating proteasome 
dysfunction underlying not only IPF but also COPD 
[37]. Ongoing projects in the Meiners laboratory 
include investigations into the role of mitochondrial 
dysfunction in cellular proteostasis and linking 
proteasome activity to cellular metabolism. While 
treatment with aspartate- or pyruvate-induced 
proteasome activity in fibroblasts, it was reduced 
by treatment with metformin. These findings open 
exciting new opportunities for understanding and 
manipulating proteostasis during ageing and 
ageing-associated chronic lung diseases such as 
IPF and COPD.
The second speaker of this session was Martina 
Korfei (Giessen, Germany), who presented on 
protein oxidation as a driver and potential target 
of pulmonary fibrosis. Proteins are folded and 
trafficked by the ER, which is dependent on a 
redox balance. Oxidative stress can cause protein 
oxidation, disrupt protein folding in the ER and 
result in increased ER stress. In this talk, Dr Korfei 
showed that protein levels of ER stress mediators 
are increased in lung homogenates and AECII in 
the lungs of IPF patients, and severe ER stress 
underlies AEC apoptosis and development of 
pulmonary fibrosis [38]. Furthermore, her research 
has identified specific transcription factor binding 
sites for induction of the proapoptotic ER stress-
related transcription factor C/EBP homologous 
protein (CHOP). These transcription factors, 
activator protein 1 and c-Ets-1, are upregulated 
in AECII from IPF patients, while overexpression 
of CHOP in vitro resulted in AECII apoptosis, lung 
fibroblast proliferation and increased production of 
collagen I [39]. This indicates CHOP activation as a 
key process of the ER stress response and a potential 
driver of pulmonary fibrosis pathogenesis. Finally, 
using a mouse model overexpressing CHOP with 
a Tet-ON system in AECII specifically, she showed 
that CHOP overexpression in vivo in AECII resulted 
in apoptosis and development of pulmonary 
fibrosis after infection with a gammaherpesvirus. In 
summary, this session highlighted the importance 
of functional proteostasis in ageing and age-related 
chronic lung disease, and provided exciting new 
insights into the link between proteostasis, immune 
function and cell metabolism.
Therapeutics targeting 
metabolic alterations 
in disease
The last session of the LSC focussed on potential 
therapies to address metabolic alterations applied 
to lung inflammation and chronic diseases, such as 
acute respiratory distress syndrome (ARDS), COPD 
and IPF.
Anna Krasnodembskaya (Belfast, UK) reported 
exciting data regarding mesenchymal stromal 
cell (MSC)-mediated mitochondrial transfer 
as a potential therapeutic strategy to protect 
mitochondria from injury or enhance biogenesis 
in cells affected by the inflammatory environment. 
Through cell–cell contact or by the release of 
extracellular vesicles, MSCs demonstrated the 
ability to carry and transfer mitochondria [40], 
resulting in metabolic reprogramming of primary 
human macrophages towards an anti-inflammatory 
phenotype [41, 42]. Transfer in mitochondria 
also resulted in the restoration of mitochondrial 
function in primary human distal lung epithelial 
and endothelial cells, and alleviated mitochondrial 
dysfunction in the impairment of the alveolar–
capillary barrier in ARDS.
In the area of chronic lung disease, Annemie 
Schols (Maastricht, the Netherlands) talked 
about how nutritional modulation could correct 
metabolic alterations in COPD. She demonstrated 
how metabolic and mechanical inefficiency may 
contribute to elevated energy expenditure during 
physical activity, and highlighted weight loss in COPD 
as a consequence of an imbalance between increased 
energy requirements and dietary intake. This leads 
to loss of muscle fibres and alteration of molecular 
markers for pathways of a mitochondrial breakdown 
in skeletal muscle of COPD patients, which are 
related to disease severity and loss of mitochondrial 
quantity [43, 44]. Challenges were presented and 
placed within the context of the future of utilising 
therapeutic targets that will address mitochondrial 
homeostasis in skeletal muscle of COPD, potentially 
leading towards new targets for maintaining or 
enhancing mitochondrial health.
The final presentation was provided by Rachel 
Chambers (London, UK), who presented mTOR 
signalling as a critical signal node during fibrogenesis 
in IPF [45, 46]. She highlighted that mTOR inhibition 
stimulated fibroblasts to restore their ability 
to support alveolar epithelial regeneration and 
proposed that targeting this axis may hold broad 
promise for the development of novel antifibrotic 
strategies, which can potentially lead to increased 
survival rates and improved quality of life for IPF 
patients. Alterations in metabolism have emerged 
as an additional hallmark of several lung conditions. 
While targeting metabolic pathways is a novel area 
with pre-clinical data suggesting efficacy, care must 
be taken to minimise adverse effects when targeting 
these pathways. Ideally, future (pre-)clinical studies 
will help to elucidate the role of cell metabolism in 
lung diseases and progression, and may lead to the 
discovery of novel therapies.
In conclusion, the overall message that 
permeated through the introductory lecture, as 
well as throughout all presentations and discussion 
sessions, was that metabolism and ageing are 
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factors we need to take into account even more 
when designing experiments, and setting up studies 
and protocols. The fact that the incidence of various 
diseases mainly occurs in older patients should also 
be represented in experimental studies by making 
use of aged rodents. Moreover, nutrition plays an 
important part in these studies, and we need to 
consider this in our experimental setup. The use 
of starvation medium or supplements can have 
inhibitory or stimulating effects on cytokine release 
from cells in in vitro studies. Although it is important 
to see all these process in light of the complexity of 
the human body, it is important to also zoom in on 
certain mechanisms every now and then.
Early career delegates session: 
strategically and successfully 
funding your future
The topic of the LSC 2020 ECMC session was 
“Strategically and successfully funding your 
future”, and included four talks covering grant 
and seminar proposal writing, and different 
fellowship opportunities within the ERS and the 
European Union (EU), with the aim of helping young 
researchers to boost their careers. The session was 
opened by the current ECMC representative for 
Assembly 3, Niki Ubags (Lausanne, Switzerland). 
She provided an introduction into the ECMC, 
and their vision and mission [47]. Moreover, she 
provided insight into opportunities for ECMs to 
become more active and involved in ERS activities.
Reinoud Gosens (Groningen, the Netherlands) 
provided an overview on how to write a convincing 
research grant. He stressed the importance of 
reading the guideline of the grant that you are 
applying for carefully and make sure to adhere 
to this guideline. It was advised to first write the 
abstract for your grant, as this provides you with 
a backbone for your application, and forces you to 
have a structured line of thought throughout the 
grant and a clear problem definition. In addition, 
if you are not sure about an idea, pitch it to your 
colleagues and get their input. His last advice 
was, "even if you do not agree with the reviewer 
comments and may be disappointed with the 
outcome, not to be defensive to the reviewers".
Dr Ubags also provided an overview of how to 
obtain a grant to organise an ERS research seminar. 
Like Dr Gosens, she mentioned that reading the 
guidelines and timely submission of the application 
is very important. Furthermore, it is necessary 
to have clear objectives, cover an unmet need, 
and clearly specify your target audience and the 
envisioned output from the seminar. This output 
should not be limited to a publication, you can also 
consider post-event activities such as a session at 
the International Congress. She further mentioned 
that it can be useful to ask the assembly heads and 
secretaries for input on your proposal, as they often 
have very valuable advice.
Next, Louise Donnelly (London, UK) talked about 
getting your first personal research grant within 
the ERS fellowship programme. She provided an 
overview of the different fellowship programmes 
that the ERS has on offer and specified the goals 
of these different programmes [48]. Moreover, 
she explained the application and interview 
process, and provided valuable do’s and don’ts for 
your applications. One of these is that you must 
choose your keywords wisely, as this determines to 
which reviewers your application will be allocated. 
Furthermore, she stressed that it is important to 
make sure that your proposed work is feasible 
for the requested fellowship time. In addition, it 
is important to highlight how the fellowship will 
advance your career and your potential involvement 
in the ERS. Lastly, Dr Donnelly mentioned that it is 
important to not give up if you are not successful 
the first time. Read the feedback carefully, integrate 
this in a resubmission and re-apply.
Lastly, Nadia El Mjyad (Brussels, Belgium) from 
the EU/European Research Council (ERC) talked 
about funding possibilities within the EU/ERC 
programme. She mentioned that for ERC starting 
grants, the excellence of the researcher and the 
research proposal are the main criteria. The host 
institute is not taken into account. It is important to 
familiarise yourself with the process and all required 
documents early on. Moreover, when selecting a 
panel to which to submit an application, it can be 
helpful to have a look at what kind of projects have 
been funded before in that panel, to make sure that 
you chose the right panel for your application. She 
also mentioned that early career researchers are 
eligible for the ERC Synergy grant mechanism.
In conclusion, the 2020 LSC provided an overview 
of excellent science on metabolic alterations in lung 
disease and career development opportunities for 
ERS ECMs. We look forward to seeing you all during 
the LSC next year.
Key messages from scientific 
sessions at LSC 2020
●● Environmental and lifestyle changes affect the 
metabolism, and these modifications can drive 
changes in gene expression, which are thought 
to cause disease or lead to an imbalance in 
health status.
●● Mitochondrial dysfunction has been implicated 
in lung ageing and the pathogenesis of lung 
diseases, which indicates the potential therapeutic 
value of mitochondria-targeted therapies and 
senotherapies for lung ageing and disease.
●● Mitochondrial dysfunction can affect several 
key functions in different lung structural cells 
during the pathogenesis of lung diseases and 
mitochondrion-derived treatments have the 
potential to mitigate progress of these conditions.
●● Proteostasis, the process of protein degradation 
that, in immune cells, results in protein display 
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via the MHC, is important in ageing and age-
related chronic lung disease.
●● ROS and oxidative stress, such as that induced 
through smoke exposure, affect proteostasis, 
protein folding and trafficking in the ER, thereby 
contributing to IPF and COPD. Regulation of 
proteostasis by metabolites (pyruvate and 
aspartate) and the drug metformin offers a 
better understanding of the process and new 
therapeutic options.
●● While targeting metabolic pathways is a novel 
area, with pre-clinical data suggesting efficacy, 
care must be taken to minimise adverse effects 
when targeting these pathways. Moreover, the 
interplay between metabolic targets and current 
therapies could be an important therapeutic 
strategy to consider as more metabolism-
targeting agents reach clinical trials in the future.
●● Ideally, future (pre-)clinical studies will help to 
elucidate the role of cell metabolism in lung 
diseases and progression, and may lead to the 
discovery of novel metabolic therapies, stratifying 
groups likely to benefit from specific intervention.
Take-home messages 
from the early career 
delegates session
●● Key steps in writing a convincing research grant 
are: 1) accurately read the guidelines; 2) start 
by writing a structured abstract; 3) pitch your 
research plan to colleagues; and 4) carefully 
consider reviewers’ comments to improve future 
or revised applications.
●● Resilience is key. Do not give up if you are not 
successful the first time around. Carefully review 
the comments and use them to improve your 
application.
●● Do not be discouraged to apply for funding 
from the ERC. If you have an outstanding 
project suggestion and the skills to carry out 
the proposed project, there are good chances 
to get far in the process.
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